108 results
Page 2 of 6
8-K
EX-99.1
vo20ur4cos qb
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
x8o 4ipbn
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
fbym4wynj69pl ml
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
8-K
EX-1.1
76q2ggegm25lhc
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
gy1o0q
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
n4ty4pt8k81j
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
akg2slskhj1
13 Sep 22
POINT Biopharma Announces Proposed Public Offering of Common Stock
4:12pm
8-K
EX-99.1
gzql 1584jdho49amg6
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
ytjmt93ad50q1y7mdcz
6 Sep 22
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
8:11am
424B3
v4zmlils4u h4a5f
11 Jul 22
Prospectus supplement
4:32pm
POS AM
ahhot
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-1.2
zufpb68d
1 Jul 22
Shelf registration
4:13pm
S-3
zoa6jlbc
1 Jul 22
Shelf registration
4:13pm
424B3
EX-99.1
s1r0h kwme1h
16 May 22
Prospectus supplement
8:27am